Trestle Biotherapeutics, a company that works on 3D-printing kidney tissue, is starting a research partnership with Humacyte, which specializes in the large-scale production of bioengineered human tissues. The main goal of this collaboration is to merge their technologies to create vascularized bioengineered organs for transplantation.
As part of this new research partnership, the leaders plan to integrate their cutting-edge technologies. This collaboration allows Trestle Bio to study the interaction between human kidney tissue and Humacyte’s blood vessels (ATEV™). The successful outcome of this collaboration would be a bioengineered kidney with the ability to sustain vascular perfusion.
New Hope for Patients with Chronic Kidney Disease
Trestle Bio is a preclinical-stage company that develops specialized bioengineered kidney tissue for patients with end-stage kidney disease. These stem cell-based tissues would allow patients to stop dialysis and delay the need for organ transplantation. In the long term, this technology lays the foundation for producing bioengineered organs, which would solve the problem of organ scarcity.
It is worth noting that Humacyte recently received FDA (U.S. Food and Drug Administration) approval for the use of its ATEV™ product, commercially known as Symvess, to treat vascular arterial injuries.
More than 800 million people worldwide suffer from chronic kidney disease (CKD). In the U.S. alone, there are 125,000 new cases of kidney failure annually, and approximately 600,000 patients depend on dialysis to survive. Around 100,000 people in America are on the waiting list for a kidney transplant, but only about 25,000 successful transplants are performed each year, highlighting a severe organ shortage problem.
According to Dr. Laura Niklason, founder and CEO of Humacyte: “Trestle is doing innovative work in a field that urgently needs new bold ideas. We are thrilled with this collaboration. It will accelerate the development of new methods to solve the problem of kidney failure.”
Ben Shepherd, co-founder and CEO of Trestle Bio, also notes: “We have been following Humacyte for a long time and can confidently say that they are setting the gold standard for developing regenerative medicine products. The broad potential of Humacyte’s ATEV technology for patients with kidney disease is obvious.”
source:
Trestle Bio Announces Research Collaboration with Humacyte, March 6, 2025.
Trestle Bio and Humacyte Form Research Collaboration, March 11, 2025.
